Joel Litman Alpha Profit Code Review (Altimetry) Top Stock Picks

view original post

Joel Litman to Introduce Top Stock Picks Poised to Benefit from a $12 Trillion Trend

The latest presentation sponsored by Altimetry Research started off by affirming a fact. What might this fact be? It turns out that collectively, Americans spend $10 billion per day on their health, and on average, humans are living much longer than they used to. Former forensic accountant and present chief investment strategist of Altimetry, Joel Litman insists that he’s discovered “the surface of a brewing revolution” linked to medical advancements.

Considering it one of the most critical industries on the planet, the expert strongly believes that companies that fall within this $12 trillion market are likely to see billions in profit. And what about the perks for investors? The returns can easily range between 250 and 1000%. Curious as to how you might be able to tap into this investment opportunity that Joel refers to as, “the Alpha Profit Code”?

Through an integrated system, he trusts that he landed on “five stocks that have the capacity to be massive winners” all of which have a part to play in the health technology industry. To our surprise, the expert revealed one of them being CVS Health (CVS), a retail pharmacy company. But to get hold of the remaining four, individuals/investors must first become a member of the Hidden Alpha.

What is Hidden Alpha?

Hidden Alpha is an investment-related research service that provides insight on profitable large-capitalization stocks that are neither visible to Wall Street nor reviewed in the media. This idea that investors can tap into such profit-generating potentials before a large portion of conventional investors is what led the service to be titled “Hidden Alpha.” From everything that we discussed so far, one thing is certain: the foundation of this service involves deciphering discrepancies in the GAAP and understanding what they might mean for a company in the time to come.

How does Hidden Alpha work?

As maintained by Joel, this service combines the expertise of over 100 people ranging from financial analysts to accountants who study U.S. stocks extensively. By employing Altimetry’s forensic accounting system, data on discovered stocks are fed into “The Altimeter”, which then filters out over 200 companies with major discrepancies. It is only after running an earnings call (i.e., looking for deception, evasion, excitement generated by CFOs and/or CEOs, etc.) on the selected picks do the team settle on 30 stocks that have massive upside. Lastly, the top 30 are sorted by size and volatility, and the safe ones are picked out and disclosed through Hidden Alpha.

What does a membership to Hidden Alpha comprise of?

By becoming a member of Joel Litman’s Alpha Profit Code by Altimetry today, individuals will get access to special reports that provide details on the four remaining stocks. Regarding his first reveal, CVS Health, the expert explained that filling a prescription at CVS implies that information gets logged in. This allows pharmacists to estimate when a refill is needed.

In addition, this pharmacy also has integrated within their system, Care mark – a prescription delivery service, and has since purchased the third largest provider of health insurance, Aetna. Simply put, they have every conceivable piece of health information at their fingertips! This is essential knowledge to have before investing in the realm of health. Fortunately, members will also have access to in depth analyses through the following:

Special Report #1. The Data King’s Billion Dollar-Bet

Inside the first special report, Joel claims to provide information on a company that provides electronic medical records, with three million health care providers using their system. Their system alone is trusted to house data on 250 million patients worldwide. That said, over the next six to 12 months, this unnamed company may double returns based on recent trends.

Special Report #2. One Stock to Rule the $657 Billion Healthtech Industry

When data is available, it is meaningless unless advanced analytics are used to model trends. This is where the next company comes into play, as they manage 498 million records, and recently inked a $925 million deal with two other companies. It’s their technology that allegedly sets them apart, and hence, could double returns over the short run. Inside this report, Joel will provide thorough analysis on the company along with the ticker symbol.

Special Report #3. Future of Medicine and the End of Cancer

The third special report revolves around the deployment of data-reliant technology and its effect on promoting personalized medicine. Interestingly, one company aims to make cancer tests widely available, “potentially preventing 100,000 cancer-related deaths every year.”

Special Report #4. The Great Hospital Shakeup

Finally comes the fourth special report, which represents yet another investment opportunity within the health technology sector. One company is in the process of merging available data with hospital care so that patient care can be improved. Matter-of-factly, this approach is what permitted this company to treat 32 million patients. More on their operations will be disclosed in this report.

Bonus #1. The Alpha Profit Code Quick-Start Guide

The above alone is a lot of information to take, but Joel decided as a bonus, he would also provide more details on the accounting flaws he ran into and how they apply to stock market analysis. This is yet another piece to the analysis puzzle that individuals can add, as accounting principles (especially discrepancies) are seldom studied.

Along with the five reports listed above, the usual incentives of Hidden Alpha include:

One full year and 12 monthly issues that unearth new stock recommendations on the first Monday of every month using Joel’s Alpha Profit Code

Access to the Hidden Alpha model portfolio coupled with detailed analyses

Full and immediate access to all archived research reports and recommendations

How much does a membership to Hidden Alpha cost?

Normally, a one-year membership to Hidden Alpha costs $199, but for a limited time, Joel is offering this Hidden Alpha Profit Code service at a discount of 75%, i.e., $49. Once it is time to renew the subscription, individuals will be charged the regular $199. If recommendations provided through Hidden Alpha fail to impress, customer service can be contacted for a full purchase price refund. For more on the steps to getting refunded, here is the necessary contact information:

  • Email: info@altimetry.com.
  • Phone: 1 (800) 701 9346 (toll-free) or (617) 229 6511 (international)
  • Contact form: click here.
  • Mailing Address: 110 Cambridge Street, Cambridge, MA 02141

Meet Editor, Joel Litman

Chief investment strategist, Joel Litman specializes in providing advice on equities, corporate credit, and macroeconomic strategy. He also taught or guest-lectured at Harvard Business School, University of Chicago Booth, Wharton, LBS, and SAIF Jiao Tong among others. At this very moment, he is a professor at Hult International Business School (i.e., a top-ranked international MBA program). Whether it be CPA or CFA chapters, he is sure to have given seminars.

To think that the aforesaid is just a fraction of Joel’s career is undreamed-of. Below are other accomplishments and contributions that the expert reached:

  • President and CEO of Valens Research
  • Member of the Board of Directors of Asian brokerage firm, COL Financial Group
  • Chair of the UAFRS Advisory Council
  • Helped build Credit Suisse’s HOLT University and the Center for S.E.V. and MBA Concentration (Driehaus College of Commerce at DePaul University)
  • Co-authored “DRIVEN: Business Strategy, Human Actions, and the Creation of Wealth”
  • Contributor to SeekingAlpha and has been published in Harvard Business Review, Barron’s, and Institutional Investor

Final Verdict

In summary, Joel’s forensic system was able to muster five health technology stocks worth investing in for immediate short- and long-term gains. Having revealed the first one as CVS Health, individuals may wonder well, isn’t it too late to invest in something that already saw quadruple gains? The answer, according to the expert, is no because this very company is poised to rack up additional double-digit gains within a matter of months. Of course, the remaining four have been hidden and will only be unearthed once individuals become member of Hidden Alpha.

On the topic of the investment service, our editorial team was fascinated by the process that Joel and his team undergo to discover best picks. Realistically, such a strategy is rarely used, which gives this team a competitive advantage. Then there’s the obvious fact that Joel has well-rounded experience in this game, which makes him a fit candidate to lead such a service. Thus, in accordance with everything seen in this review, we see value in investing in Hidden Alpha, and with its money-back guarantee, individuals are possibly presented with a risk-free option. To find out more about Hidden Alpha, click here>>>.

ALSO READ: Teeka Tiwari Biggest Wealth Transfer Act Review – Palm Beach Letter (Return of Inflation)

Affiliate Disclosure:

The links contained in this product review may result in a small commission if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products.

Disclaimer:

Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease.